Related Experiment Video

Updated: Jun 14, 2025

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

12.6K

mTOR and SGLT-2 Inhibitors: Their Synergistic Effect on Age-Related Processes

Dario Troise1,2, Silvia Mercuri1, Barbara Infante1

  • 1Nephrology, Dialysis and Transplantation Unit, Advanced Research Center on Kidney Aging (A.R.K.A.), Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.

International Journal of Molecular Sciences
|August 29, 2024
PubMed

Insights

Targeting senescent cells can extend lifespan and reduce age-related diseases. This review explores the potential synergistic benefits of combining mTOR and SGLT-2 inhibitors to combat aging.

Area of Science:

  • Gerontology and cellular senescence research.
  • Pharmacology of aging and chronic disease.
  • Metabolic pathways and cellular regulation.

Background:

  • Aging is a major risk factor for chronic diseases, leading to significant global mortality and healthcare burdens.
  • Senescent cells accumulate with age and drive age-related pathologies.
  • Current research focuses on senotherapeutics, drugs that eliminate senescent cells.

Purpose of the Study:

  • To review the potential synergistic effects of mTOR and SGLT-2 inhibitors in targeting cellular senescence.
  • To explore how these drug classes may complement each other in combating aging processes.
  • To highlight avenues for future research into combined senolytic therapies.

Main Methods:

  • Literature review of studies on mTOR inhibitors, SGLT-2 inhibitors, and cellular senescence.
  • Analysis of the known mechanisms of action for each drug class.
  • Exploration of potential interactions and synergistic effects on senescence pathways.

Main Results:

  • mTOR inhibitors modulate cellular growth, metabolism, and immunity, impacting senescence.
  • SGLT-2 inhibitors improve metabolic health through glucose reabsorption regulation.
  • Evidence suggests potential overlap and synergy in how these drugs influence senescence.

Conclusions:

  • Combining mTOR and SGLT-2 inhibitors may offer a powerful strategy for targeting senescence.
  • This combination could enhance lifespan and reduce age-related diseases.
  • Further direct studies are needed to validate the synergistic benefits of these combined therapies.
Keywords:
SGLT-2 inhibitorsaginginflammagingmTOR inhibitorssenescencesenomorphic compoundssenotherapeutic strategies

More Related Videos

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice03:17

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Published on: March 29, 2024

446
Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

18.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Mitochondria01:37

Mitochondria

Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
11.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
12.3K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178